Provided by Tiger Trade Technology Pte. Ltd.

SAB Biotherapeutics, Inc.

3.80
-0.0700-1.81%
Post-market: 3.810.0100+0.26%19:37 EDT
Volume:5.65M
Turnover:21.48M
Market Cap:290.56M
PE:-1.85
High:3.95
Open:3.81
Low:3.68
Close:3.87
52wk High:6.60
52wk Low:1.67
Shares:76.46M
Float Shares:54.30M
Volume Ratio:5.70
T/O Rate:10.41%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.0498
EPS(LYR):-0.7944
ROE:-0.32%
ROA:-25.38%
PB:1.28
PE(LYR):-4.78

Loading ...

U.S. Research Roundup-caseys General Stores, Micron Technology, SAP

Reuters
·
Jun 25

SAB Biotherapeutics Initiated at Overweight by Barclays

Dow Jones
·
Jun 25

Barclays Initiates SAB Biotherapeutics at Overweight With $13 Price Target

MT Newswires Live
·
Jun 24

SAB Biotherapeutics shareholders elect four Class II directors at annual meeting

Reuters
·
Jun 19

SAB Biotherapeutics Is Maintained at Buy by Chardan Capital

Dow Jones
·
Jun 17

Chardan Adjusts Price Target on SAB Biotherapeutics to $16 From $14, Maintains Buy Rating

MT Newswires Live
·
Jun 17

Analysts Are Bullish on Top Healthcare Stocks: Ryman Healthcare (RHCGF), SAB Biotherapeutics (SABS)

TIPRANKS
·
Jun 17

Craig-Hallum Remains a Buy on SAB Biotherapeutics (SABS)

TIPRANKS
·
Jun 16

SAB Biotherapeutics Price Target Maintained With a $10.00/Share by HC Wainwright & Co.

Dow Jones
·
Jun 15

SAB Biotherapeutics to present SAB-142 data at ADA Scientific Sessions

Reuters
·
May 29

SAB Biotherapeutics Initiated at Buy by Citigroup

Dow Jones
·
May 22

Citigroup Initiates SAB Biotherapeutics at Buy With $11 Price Target

MT Newswires Live
·
May 22

SAB Biotherapeutics initiated with a Buy at Citi

TIPRANKS
·
May 22

Jefferies Initiates SAB Biotherapeutics at Buy With $11 Price Target

MT Newswires Live
·
May 20

Analysts’ Top Healthcare Picks: Hims & Hers Health (HIMS), SAB Biotherapeutics (SABS)

TIPRANKS
·
May 20

SAB Biotherapeutics initiated with a Buy at Jefferies

TIPRANKS
·
May 20

Analysts Conflicted on These Healthcare Names: Qiagen (QGEN), SAB Biotherapeutics (SABS) and Moderna (MRNA)

TIPRANKS
·
May 14

Chardan Capital Keeps Their Buy Rating on SAB Biotherapeutics (SABS)

TIPRANKS
·
May 13

SAB Biotherapeutics price target raised to $10 from $7 at H.C. Wainwright

TIPRANKS
·
May 13

SAB Biotherapeutics Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
May 13